2-Methyl-1-pyrrolidinecarboxylic acid | 41353-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-Methyl-1-pyrrolidinecarboxylic acid
• 英文别名: 2-methylpyrrolidine-1-carboxylic acid
• CAS: 41353-48-4
• 化学式: C₆H₁₁NO₂
• 分子量: 129.16
• InChiKey: GULMJNUJAVNDBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] IMMUNOPROTEASOME INHIBITORS<br/>[FR] INHIBITEURS D'IMMUNOPROTÉASOME
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2018136401A1

  公开（公告）日：2018-07-26

  Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本文提供了化合物，例如所述的化合物的化学式(I)，或其药用可接受的盐，这些化合物是免疫蛋白酶体（如LMP2和LMP7）抑制剂。本文描述的化合物可用于治疗通过抑制免疫蛋白酶体可治疗的疾病。本文还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
  申请人：GENZYME CORPORATION

  公开号：US20200102324A1

  公开（公告）日：2020-04-02

  Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

  本文描述了一种化合物，其化学式为（I），以及其药用盐。本文还描述了这些组合物以及在治疗各种疾病和症状的方法中使用这些组合物，特别是克拉贝氏病（KD）和间染色质白质脑病（MLD）。
• [EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012125893A1

  公开（公告）日：2012-09-20

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

  本发明提供了化合物I的公式及其药学上可接受的盐。公式I的化合物抑制JAK3的酪氨酸激酶活性，因此使它们在治疗炎症和自身免疫性疾病方面具有用途。
• CDK2 INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20200247784A1

  公开（公告）日：2020-08-06

  This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用盐，其中R1、R2和R3如本文所定义。该发明还涉及包括这些化合物和盐的药物组合物，以及使用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。
• Long chain aliphatic alcohol derivatives and methods of making and using same
  申请人：Milanova Radka

  公开号：US20060020135A1

  公开（公告）日：2006-01-26

  This application pertains to compounds comprising unbranched long chain aliphatic alcohols linked to a heterocyclic carboxylic acid moiety by means of an ester or ether linkage. The aliphatic alcohols may include aliphatic alcohols present in polycosanol, such as octacosanol. The heterocyclic carboxylic acid moieties include a 5-membered ring, a 6-membered ring, or a bicyclic ring. In one embodiment, the compounds of the invention include 1-octacosanyl nicotinate and salts thereof. The invention includes prodrugs, pharmaceutically acceptable salts, and pharmaceutical compositions of the compounds, and methods of making and using the compounds.

  该应用涉及由直链长链脂肪醇与杂环羧酸基团通过酯或醚键连接而成的化合物。脂肪醇可能包括聚角醇中存在的脂肪醇，如辛醇。杂环羧酸基团包括5元环、6元环或双环。在一个实施例中，该发明的化合物包括1-辛醇基烟酸酯及其盐。该发明包括前药、药学上可接受的盐以及该化合物的药物组合物，以及制备和使用该化合物的方法。